UPB earnings

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl